← Leaderboards
Maria Lambros
Doricpharma Llc
$453,754
Attributed
$453,754
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $401.8K · FY2020–21$500K$375K$250K$125K$0
'20
'21
Funding mix
By agency
NIH$453,754 · 1
By mechanism
R41$453,754 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Gemcitabine”
- William Andrew Daunch · Focal Medical, Inc.$6,184,629
- Bryce Beverlin II · Quench Medical, Inc.$2,651,805
- Andrea Viale · University Of Tx Md Anderson Can Ctr$2,258,753
- Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor$2,195,997
- Satyanarayana Rachagani · University Of Missouri-Columbia$2,046,118
- Joe Assouline · Nanomedtrix, Llc$2,000,000
Research focus
GemcitabineHigh Dose ChemotherapyEncapsulatedExtracellularGrowthBiodistributionAntineoplastic AgentsCancer CellCancer PatientAdverse EffectsGoldChemotherapyCysteineCystineDesignDiagnosisDoseDrug CarriersDrug Delivery SystemsDrug KineticsDrug TargetingEarly DiagnosisChemotherapeutic AgentLegal Patent
Grant awards (3)
Using Targeted Lipid Nanoparticles to Deliver Chemotherapeutic Agents against Pancreatic Cancer$52,000
R41 · FY2021 · CA · contact PI
Using Targeted Lipid Nanoparticles to Deliver Chemotherapeutic Agents against Pancreatic Cancer$299,559
R41 · FY2020 · CA · contact PI
Using Targeted Lipid Nanoparticles to Deliver Chemotherapeutic Agents against Pancreatic Cancer$102,195
R41 · FY2020 · CA · contact PI